The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt Original Research Article

Background The population of Egypt has a heavy burden of liver disease, mostly due to chronic infection with hepatitis C virus (HCV). Overall prevalence of antibody to HCV in the general population is around 15–20%. The risk factor for HCV transmission that specifically sets Egypt apart from other countries is a personal history of parenteral antischistosomal therapy (PAT). A review of the Egyptian PAT mass-treatment campaigns, discontinued only in the 1980s, show a very high potential for transmission of blood-bome pathogens. We examine the relative importance of PAT in the spread of HCV in Egypt. Methods The degree of exposure to PAT by cohort was estimated from 1961–86 Ministry of Health data. A cohort-specific exposure index for PAT was calculated and compared with cohort-specific HCV prevalence rates in four regions. Findings HCV prevalence was calculated for 8499 Egyptians aged 10–50 years. A significant association between seroprevalence of antibodies to HCV and the exposure index (1.31 [95% CI 1.08–1.59]; p=0.007) was identified across four different regions. In all regions cohort-specific HCV prevalence was lowest in children and young adults than in older cohorts. These lower prevalence rates coincided with the gradual and final replacement of PAT with oral antischistosomal drugs at different points in time in the four regions. Interpretation The data suggest that PAT had a major role in the spread of HCV throughout Egypt. This intensive transmission established a large reservoir of chronic HCV infection, responsible for the high prevalence of HCV infection and current high rates of transmission. Egyptʹs mass campaigns of PAT may represent the worldʹs largest iatrogenic transmission of blood-borne pathogens.